171 related articles for article (PubMed ID: 36685039)
21. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
[TBL] [Abstract][Full Text] [Related]
22. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
Abongomera C; Diro E; Vogt F; Tsoumanis A; Mekonnen Z; Admassu H; Colebunders R; Mohammed R; Ritmeijer K; van Griensven J
Clin Infect Dis; 2017 Oct; 65(10):1703-1710. PubMed ID: 29020196
[TBL] [Abstract][Full Text] [Related]
23. Leishmania / HIV co-infections.
Desjeux P
Afr Health; 1995 Nov; 18(1):20-2. PubMed ID: 12290565
[TBL] [Abstract][Full Text] [Related]
24. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ
AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of disease severity in patients with visceral leishmaniasis co-infected with HIV.
Ferreira GR; Santos-Oliveira JR; Silva-Freitas ML; Honda M; Costa DL; Da-Cruz AM; Costa CHN
Cytokine; 2022 Jan; 149():155747. PubMed ID: 34715475
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
[TBL] [Abstract][Full Text] [Related]
27. Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8
Rodrigues LS; Barreto AS; Bomfim LGS; Gomes MC; Ferreira NLC; da Cruz GS; Magalhães LS; de Jesus AR; Palatnik-de-Sousa CB; Corrêa CB; de Almeida RP
Front Immunol; 2021; 12():773983. PubMed ID: 34777391
[TBL] [Abstract][Full Text] [Related]
28. Relapsing visceral leishmaniasis in a HIV-1 infected patient with advanced disease.
Standaert D; Laurent F; Jonckheere S; Scheiff JM; Vandercam B; Yombi JC
Acta Clin Belg; 2013; 68(2):124-7. PubMed ID: 23967722
[TBL] [Abstract][Full Text] [Related]
29. High levels of CD4⁺ CTLA-4⁺ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis.
Vallejo A; Abad-Fernández M; Moreno S; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):267-75. PubMed ID: 25142804
[TBL] [Abstract][Full Text] [Related]
30. Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies.
Song S; Gui X; Guan L
Emerg Microbes Infect; 2014 Apr; 3(4):e24. PubMed ID: 26038517
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
32. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
33. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function.
Esch KJ; Juelsgaard R; Martinez PA; Jones DE; Petersen CA
J Immunol; 2013 Dec; 191(11):5542-50. PubMed ID: 24154626
[TBL] [Abstract][Full Text] [Related]
34. Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation.
Takele Y; Adem E; Franssen SU; Womersley R; Kaforou M; Levin M; Müller I; Cotton JA; Kropf P
PLoS Negl Trop Dis; 2022 Jun; 16(6):e0010544. PubMed ID: 35749568
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia.
Alemayehu M; Wubshet M; Mesfin N; Tamiru A; Gebayehu A
Health Qual Life Outcomes; 2017 Aug; 15(1):65. PubMed ID: 28851361
[TBL] [Abstract][Full Text] [Related]
36. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.
d'Ettorre G; Ceccarelli G; Carnevalini M; Forcina G; Zaffiri L; Massetti AP; Mastroianni CM; Vullo V
Acta Trop; 2006 Aug; 99(1):83-7. PubMed ID: 16962979
[TBL] [Abstract][Full Text] [Related]
37. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.
Cota GF; de Sousa MR; de Mendonça AL; Patrocinio A; Assunção LS; de Faria SR; Rabello A
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2816. PubMed ID: 24743472
[TBL] [Abstract][Full Text] [Related]
38. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections.
Russo R; Laguna F; López-Vélez R; Medrano FJ; Rosenthal E; Cacopardo B; Nigro L
Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():99-105. PubMed ID: 14678637
[TBL] [Abstract][Full Text] [Related]
39. Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review.
Alemayehu M; Wubshet M; Mesfin N
HIV AIDS (Auckl); 2016; 8():75-81. PubMed ID: 27042142
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection.
Medrano FJ; Rey C; Leal M; Cañavate C; Rubio A; Sánchez-Quijano A; Alvar J; Lissen E
Clin Exp Immunol; 1998 Dec; 114(3):403-7. PubMed ID: 9844050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
